Selected research
Industry Research
Ornithine-Transcarbamylase Deficiency Industry Research Report 2026
Market perspective
The global Ornithine-Transcarbamylase Deficiency market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ornithine-Transcarbamylase Deficiency is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ornithine-Transcarbamylase Deficiency is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Ornithine-Transcarbamylase Deficiency is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ornithine-Transcarbamylase Deficiency include Lucane Pharma SA, PhaseRx Inc, Promethera Biosciences SA, Selecta Biosciences Inc, Translate Bio Inc, Ultragenyx Pharmaceutical Inc and Unicyte AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ornithine-Transcarbamylase Deficiency market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ornithine-Transcarbamylase Deficiency Market by Company
Lucane Pharma SA
PhaseRx Inc
Promethera Biosciences SA
Selecta Biosciences Inc
Translate Bio Inc
Ultragenyx Pharmaceutical Inc
Unicyte AG
Ornithine-Transcarbamylase Deficiency Segment by Type
SHP-641
SEL-313
PRX-OTC
DTX-301
Others
Ornithine-Transcarbamylase Deficiency Segment by Application
Hospital
Clinic
Others
Ornithine-Transcarbamylase Deficiency Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ornithine-Transcarbamylase Deficiency market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ornithine-Transcarbamylase Deficiency and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ornithine-Transcarbamylase Deficiency.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ornithine-Transcarbamylase Deficiency manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ornithine-Transcarbamylase Deficiency by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ornithine-Transcarbamylase Deficiency in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- SHP-641
- SEL-313
- PRX-OTC
- DTX-301
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Lucane Pharma SA
- PhaseRx Inc
- Promethera Biosciences SA
- Selecta Biosciences Inc
- Translate Bio Inc
- Ultragenyx Pharmaceutical Inc
- Unicyte AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Ornithine-Transcarbamylase Deficiency Market Size (2021-2032)
- 2.2.2 Global Ornithine-Transcarbamylase Deficiency Sales (2021-2032)
- 2.2.3 Global Ornithine-Transcarbamylase Deficiency Market Average Price (2021-2032)
- 2.3 Ornithine-Transcarbamylase Deficiency by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 SHP-641
- 2.3.3 SEL-313
- 2.3.4 PRX-OTC
- 2.3.5 DTX-301
- 2.3.6 Others
- 2.4 Ornithine-Transcarbamylase Deficiency by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Ornithine-Transcarbamylase Deficiency Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Ornithine-Transcarbamylase Deficiency Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Ornithine-Transcarbamylase Deficiency Revenue of Manufacturers (2021-2026)
- 3.4 Global Ornithine-Transcarbamylase Deficiency Average Price by Manufacturers (2021-2026)
- 3.5 Global Ornithine-Transcarbamylase Deficiency Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Ornithine-Transcarbamylase Deficiency, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Ornithine-Transcarbamylase Deficiency, Product Type & Application
- 3.8 Global Manufacturers of Ornithine-Transcarbamylase Deficiency, Established Date
- 3.9 Global Ornithine-Transcarbamylase Deficiency Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Lucane Pharma SA
- 4.1.1 Lucane Pharma SA Company Information
- 4.1.2 Lucane Pharma SA Business Overview
- 4.1.3 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Lucane Pharma SA Ornithine-Transcarbamylase Deficiency Product Portfolio
- 4.1.5 Lucane Pharma SA Recent Developments
- 4.2 PhaseRx Inc
- 4.2.1 PhaseRx Inc Company Information
- 4.2.2 PhaseRx Inc Business Overview
- 4.2.3 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 PhaseRx Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 4.2.5 PhaseRx Inc Recent Developments
- 4.3 Promethera Biosciences SA
- 4.3.1 Promethera Biosciences SA Company Information
- 4.3.2 Promethera Biosciences SA Business Overview
- 4.3.3 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Promethera Biosciences SA Ornithine-Transcarbamylase Deficiency Product Portfolio
- 4.3.5 Promethera Biosciences SA Recent Developments
- 4.4 Selecta Biosciences Inc
- 4.4.1 Selecta Biosciences Inc Company Information
- 4.4.2 Selecta Biosciences Inc Business Overview
- 4.4.3 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Selecta Biosciences Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 4.4.5 Selecta Biosciences Inc Recent Developments
- 4.5 Translate Bio Inc
- 4.5.1 Translate Bio Inc Company Information
- 4.5.2 Translate Bio Inc Business Overview
- 4.5.3 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Translate Bio Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 4.5.5 Translate Bio Inc Recent Developments
- 4.6 Ultragenyx Pharmaceutical Inc
- 4.6.1 Ultragenyx Pharmaceutical Inc Company Information
- 4.6.2 Ultragenyx Pharmaceutical Inc Business Overview
- 4.6.3 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ultragenyx Pharmaceutical Inc Ornithine-Transcarbamylase Deficiency Product Portfolio
- 4.6.5 Ultragenyx Pharmaceutical Inc Recent Developments
- 4.7 Unicyte AG
- 4.7.1 Unicyte AG Company Information
- 4.7.2 Unicyte AG Business Overview
- 4.7.3 Unicyte AG Ornithine-Transcarbamylase Deficiency Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Unicyte AG Ornithine-Transcarbamylase Deficiency Product Portfolio
- 4.7.5 Unicyte AG Recent Developments
5 Global Ornithine-Transcarbamylase Deficiency Market Scenario by Region
- 5.1 Global Ornithine-Transcarbamylase Deficiency Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Ornithine-Transcarbamylase Deficiency Sales by Region: 2021-2032
- 5.2.1 Global Ornithine-Transcarbamylase Deficiency Sales by Region: 2021-2026
- 5.2.2 Global Ornithine-Transcarbamylase Deficiency Sales by Region: 2027-2032
- 5.3 Global Ornithine-Transcarbamylase Deficiency Revenue by Region: 2021-2032
- 5.3.1 Global Ornithine-Transcarbamylase Deficiency Revenue by Region: 2021-2026
- 5.3.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Region: 2027-2032
- 5.4 North America Ornithine-Transcarbamylase Deficiency Market Facts & Figures by Country
- 5.4.1 North America Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 5.4.3 North America Ornithine-Transcarbamylase Deficiency Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Ornithine-Transcarbamylase Deficiency Market Facts & Figures by Country
- 5.5.1 Europe Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 5.5.3 Europe Ornithine-Transcarbamylase Deficiency Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Ornithine-Transcarbamylase Deficiency Market Facts & Figures by Country
- 5.6.1 Asia Pacific Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Ornithine-Transcarbamylase Deficiency Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Ornithine-Transcarbamylase Deficiency Market Facts & Figures by Country
- 5.7.1 South America Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 5.7.3 South America Ornithine-Transcarbamylase Deficiency Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Ornithine-Transcarbamylase Deficiency Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Ornithine-Transcarbamylase Deficiency Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Ornithine-Transcarbamylase Deficiency Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2032)
- 6.1.1 Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Ornithine-Transcarbamylase Deficiency Sales Market Share by Type (2021-2032)
- 6.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Type (2021-2032)
- 6.2.1 Global Ornithine-Transcarbamylase Deficiency Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Type (2021-2032)
- 6.3 Global Ornithine-Transcarbamylase Deficiency Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2032)
- 7.1.1 Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Ornithine-Transcarbamylase Deficiency Sales Market Share by Application (2021-2032)
- 7.2 Global Ornithine-Transcarbamylase Deficiency Revenue by Application (2021-2032)
- 7.2.1 Global Ornithine-Transcarbamylase Deficiency Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Ornithine-Transcarbamylase Deficiency Revenue Market Share by Application (2021-2032)
- 7.3 Global Ornithine-Transcarbamylase Deficiency Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Ornithine-Transcarbamylase Deficiency Value Chain Analysis
- 8.1.1 Ornithine-Transcarbamylase Deficiency Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Ornithine-Transcarbamylase Deficiency Production Mode & Process
- 8.2 Ornithine-Transcarbamylase Deficiency Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Ornithine-Transcarbamylase Deficiency Distributors
- 8.2.3 Ornithine-Transcarbamylase Deficiency Customers
9 Global Ornithine-Transcarbamylase Deficiency Analyzing Market Dynamics
- 9.1 Ornithine-Transcarbamylase Deficiency Industry Trends
- 9.2 Ornithine-Transcarbamylase Deficiency Industry Drivers
- 9.3 Ornithine-Transcarbamylase Deficiency Industry Opportunities and Challenges
- 9.4 Ornithine-Transcarbamylase Deficiency Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst